Effectiveness and safety of erenumab, galcanezumab and fremanezumab in migraine: real world data results

被引：0
|
作者：
Castano-Amores, C. [1 ]
Nieto-Gomez, P. [2 ]
Alvarez-Sanchez, R. [1 ]
机构：
[1] Hosp Univ San Cecilio, Pharm Unit, Granada, Spain
[2] Hosp Gutierrez Ortega, Pharm Unit, Valdepenas, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2022年 / 44卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PP05
引用
收藏
页码：819 / 820
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice
    Cantarelli, Lorenzo
    Grafina, Diana Pestana
    Perez, Amanda Gonzalez
    Gil, Sara Garcia
    Nicolas, Fernando Gutierrez
    Santana, Emma Ramos
    Navarro Davila, Marco Antonio
    Otazo Perez, Sheila Maria
    Gomez, Gloria Calzado
    Reyes, Sergio Perez
    Nazco Casariego, Gloria Julia
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (04) : 416 - 424
  • [2] Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab
    Talbot, Jamie
    Stuckey, Rebecca
    Wood, Natasha
    Gordon, Alexander
    Crossingham, Ginette
    Weatherby, Stuart
    [J]. EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024,
  • [3] Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients
    Curone, Marcella
    Tullo, Vincenzo
    Didier, Henri Albert
    Bussone, Gennaro
    [J]. NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5759 - 5761
  • [4] Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients
    Marcella Curone
    Vincenzo Tullo
    Henri Albert Didier
    Gennaro Bussone
    [J]. Neurological Sciences, 2022, 43 : 5759 - 5761
  • [5] Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience
    Mahovic, Darija
    Bracic, Matea
    Jakus, Lukrecija
    Cvetkovic, Vlasta Vukovic
    Krpan, Marina
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2022, 214
  • [6] CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab
    De Luca, Ciro
    Baldacci, Filippo
    Mazzucchi, Sonia
    Lombardo, Irene
    Curto, Letizia
    Ulivi, Martina
    Chico, Lucia
    Papa, Michele
    Siciliano, Gabriele
    Gori, Sara
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [7] Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study
    Viudez-Martinez, Adrian
    Pascual-Carrasco, Angela
    Beltran-Blasco, Isabel
    Hernandez-Lorido, Raquel
    de Apodaca, Rosa F. Ruiz
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (06) : 814 - 823
  • [8] Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain
    Irimia, Pablo
    Santos-Lasaosa, Sonia
    Garcia Bujalance, Laura
    Ramos Pinazo, Luis
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 285 - 297
  • [9] Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine
    Quintana, Simone
    Russo, Marco
    Manzoni, Gian Camillo
    Torelli, Paola
    [J]. NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5757 - 5758
  • [10] Real-world effectiveness of erenumab in Japanese patients with migraine
    Suzuki, Keisuke
    Suzuki, Shiho
    Shiina, Tomohiko
    Haruyama, Yasuo
    Kobayashi, Saro
    Shioda, Mukuto
    Hirata, Koichi
    [J]. HELIYON, 2024, 10 (04)
12345